Asieris Pharmaceuticals
Asieris Pharmaceuticals is a publicly traded Chinese biopharmaceutical company developing first-in-class therapies for genitourinary tumors and women's health, with marketed products including Cevira, Hexvix, Vesique, and oncology generics distributed through Sinopharm in China.
- Company typePublic
- Founded2010
- HeadquartersShanghai, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Asieris Pharmaceuticals does
Asieris Pharmaceuticals is a Chinese innovative biopharmaceutical company founded in 2010 in Taizhou, Jiangsu Province, and publicly listed on the Shanghai STAR Market (688176.SH) since January 2022 when it raised CNY 2.528 billion. The company is a subsidiary of Jiangsu Yahong Meditech Co., Ltd. and operates R&D centers in Shanghai and Palo Alto, California, with global clinical operations across China, the US, and Europe. Its therapeutic focus is genitourinary tumors and women's health, with three primary platforms: TIMN (Targeted Immunomodulator Normalization), TAIDD (Targeted & AI-driven Drug Discovery), and DDC (Drug Device Combination) built on PADD (Prodrugs Accurate Drug Delivery) technology.
The company's commercial portfolio spans six marketed products. Cevira (APL-1702) is a first-in-class photodynamic drug-device combination therapy for cervical HSIL/CIN2 licensed from Photocure and approved by NMPA in March 2026. Hexvix (APL-1706), also from Photocure, is the world's only approved imaging agent for bladder cancer diagnosis, approved in China in November 2024. Vesique (APL-1202) is an oral MetAP2 inhibitor for non-muscle invasive bladder cancer (NMIBC) in pivotal Phase III trials. Dipaite (pazopanib), Ouyoubi (neratinib), and Ounalin (eribulin) are oncology products approved in China during 2023-2025. Pipeline assets include ADC candidates from Baylink Biosciences, a USP1 inhibitor (APL-2302), an FGFR2/3 inhibitor (APL-2401), and a UC therapy (APL-1401).
Revenue is generated through a hybrid model combining direct hospital sales in China, channel partnerships with Sinopharm and SPH Kyuan Trade for distribution and logistics, and out-licensing arrangements (e.g., Cevira global rights, APL-2302). The company sells prescription pharmaceuticals at prices determined through Chinese national reimbursement and hospital procurement systems rather than public list pricing. End customers are healthcare providers and patients; clinical collaborators include academic centers (Peking Union Medical College Hospital, Mount Sinai, UCSF Medical Center). The company reported revenue exceeding RMB 200 million in its first year of commercialization (2024).
Asieris Pharmaceuticals firmographics
Firmographics- Name
- Asieris Pharmaceuticals
- Legal name
- Jiangsu Asieris Pharmaceuticals Co., Ltd.
- Website
- https://asieris.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Asieris Pharmaceuticals is a publicly traded Chinese biopharmaceutical company developing first-in-class therapies for genitourinary tumors and women's health, with marketed products including Cevira, Hexvix, Vesique, and oncology generics distributed through Sinopharm in China.
- Ownership category
- akta.pro rank
Asieris Pharmaceuticals industry classification
Industry- Product category
- Genitourinary Oncology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
- akta.pro secondary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Asieris Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices7 records
Markets served
Asieris Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Product Sales - Marketed Pharmaceuticals: Revenue from commercialized products including Hexvix for bladder cancer diagnosis, Dipaite (pazopanib) for renal cell carcinoma, Ouyoubi (neratinib) for breast cancer, and Ounalin (eribulin) for metastatic breast cancer. Products launched in China starting 2023-2025.
- Licensing and Milestone Payments: As the licensor of Cevira technology to Asieris, Photocure receives milestone payments tied to regulatory approvals in China and Europe, plus sales royalties. For Asieris, this represents costs rather than revenue.
- Out-Licensing Revenue: Asieris has out-licensed APL-1702 (Cevira) and APL-2302 for global development, receiving upfront payments, milestone payments upon achievement of clinical and regulatory milestones, and sales royalties.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Asieris Pharmaceuticals product offering
Product offeringCore offering
Asieris Pharmaceuticals is a global innovative biopharma company that develops, manufactures, and commercializes drugs for genitourinary tumors and women's health. It sells marketed pharmaceutical products including bladder cancer imaging agents, oral therapies for non-muscle invasive bladder cancer (NMIBC), renal cell carcinoma treatments, HER2+ breast cancer therapies, and the first non-surgical photodynamic therapy for cervical precancerous lesions (Cevira). It also operates proprietary drug discovery platforms (TIMN, TAIDD, DDC) supporting an in-house pipeline of small molecules, photodynamic drug-device combinations, and antibody-drug conjugates.
Product overview
Asieris Pharmaceuticals is a global innovative biopharma company specializing in genitourinary tumors and women's health. The company's portfolio comprises both marketed products and an extensive pipeline. Marketed products include: Hexvix (APL-1706), the world's only approved imaging agent for bladder cancer diagnosis; Vesique (APL-1202), the first oral targeted NMIBC therapy; Dipaite (Pazopanib Tablets) for renal cell carcinoma; Ouyoubi (Neratinib Maleate Tablets) for HER2+ breast cancer; and Ounalin (Eribulin Mesylate Injection) for metastatic breast cancer. Core products in development include CEVIRA (APL-1702), the world's first non-surgical photodynamic therapy for cervical precancerous lesions (CIN2), and the APL-1202 franchise for bladder cancer. The pipeline spans urological oncology, women's health, breast and gynecologic oncology, and other diseases including ulcerative colitis and antibiotic-resistant infections. The company operates three technology platforms: TIMN (Targeted Immunomodulator Normalization), TAIDD (Targeted & AI-driven Drug Discovery), and DDC (Drug Device Combination).
Differentiator
Problem solved
Functional benefit
Products and services
- Cevira (APL-1702) World's first non-surgical, non-invasive photodynamic drug-device combination therapy for cervical high-grade squamous intraepithelial lesions (HSIL/CIN2), combining a photosensitizer with light activation to treat HPV-induced cervical precancerous lesions while preserving fertility. For women of childbearing age with cervical precancerous lesions.
- Hexvix (APL-1706) The world's only approved imaging agent for assisting in the diagnosis and surgery of bladder cancer. Used with Blue Light Cystoscopy (BLC) to improve detection of NMIBC, especially carcinoma in situ. For urologists and hospitals performing bladder cancer surgery.
- Vesique (APL-1202) First oral targeted therapy for non-muscle invasive bladder cancer (NMIBC); the world's first oral and reversible MetAP2 inhibitor under clinical development. Targets both tumor cell growth and angiogenesis, offering an oral alternative to intravesical administration. For NMIBC patients lacking oral therapy options.
- Dipaite (Pazopanib Tablets) Approved for first-line treatment of patients with advanced renal cell carcinoma and for treatment of patients who have received cytokine therapy. Among the first wave of domestic generic launches in China. For oncologists treating advanced RCC.
- Ouyoubi (Neratinib Maleate Tablets) Approved for extended adjuvant treatment of adult patients with HER2-positive early breast cancer following adjuvant trastuzumab-based therapy. First domestic generic of neratinib maleate tablets in China. For HER2+ early breast cancer patients in adjuvant setting.
- Ounalin (Eribulin Mesylate Injection) Approved for treatment of locally advanced or metastatic breast cancer in patients previously treated with at least two chemotherapy regimens including anthracycline and taxane. For metastatic breast cancer patients.
- Blue Light Cystoscopy System Blue Light Cystoscopy System approved for marketing in China for precision treatment of bladder cancer, supporting Hexvix-based photodynamic detection of NMIBC.
Quantifiable outcome
- Phase III trial: 89.4% higher response rate vs placebo (41.1% vs 21.7%, p=0.0001); 103.9% increase in HPV clearance (31.4% vs 15.4%)
- +3 more outcomes
Companies that use Asieris Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
Asieris Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Asieris Pharmaceuticals partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, regulatory, strategic and core.
- SPH Kyuan TrademajorImport and distribution strategic partnership to accelerate commercialization of Cevira in China. Announced March 2026.
- BSI GroupregulatoryNotified body for CE application submission for bladder cancer product APLD-2304. BSI Group received the technical documentation for review.
- SPH Keyuan TrademajorStrategic cooperation agreement signed at CIIE for import and distribution of Asieris products in China.
- East China University of Science and Technology (ECUST)strategicStrategic partnership with ECUST's School of Chemistry and Molecular Engineering for photodynamic platforms research and development collaboration.
- UroViustrategicDeepened strategic partnership to further develop integrated diagnosis and treatment platform for bladder cancer. UroViu provides single-use endoscopy products for bladder disease diagnosis.
- ReviRstrategicResearch collaboration agreement to discover oncology therapeutics based on ReviR's comprehensive approach to RNA-targeting technologies.
- SinopharmcoreStrategic collaboration for commercialization, logistics and supply chain services. Sinopharm provides extensive pharmaceutical marketing network and strong market service capabilities to accelerate product distribution. First project under partnership was Hexvix commercialization.
- BeiGenecoreClinical collaboration to evaluate oral APL-1202 in combination with tislelizumab (anti-PD-1 antibody) as neoadjuvant therapy for muscle invasive bladder cancer (MIBC). Open-label, multi-center Phase I/II clinical study planned for China and US.
- Lecheng SinopharmmajorStrategic cooperation agreement to introduce and provide innovative drugs and medical devices to Boao Lecheng International Medical Tourism Pilot Zone. Both companies work together to promote project implementation and participate in Clinical Real World Data pilot research center.
- Photocure ASAcoreLicense agreement to exclusively register and commercialize Hexvix in Mainland China and Taiwan. Hexvix is a diagnostic drug that makes bladder cancer cells glow bright pink during Blue Light Cystoscopy for NMIBC detection.
- Photocure ASAcoreWorldwide licensing agreement for development and commercialization of Cevira (APL-1702) for HPV-induced cervical precancerous lesions. Asieris paid USD 5 million signing fee with potential USD 18 million for China clinical/regulatory milestones and USD 36 million for US/EU milestones, plus sales royalties. Asieris assumed manufacturing responsibility while Photocure retains API manufacturing.
- China Women's Development FoundationstrategicStrategic cooperation agreement for 'Fertility-Friendly Cervical Health Initiative' to promote cervical health awareness and access to treatment.
- Cancer Foundation of ChinastrategicStrategic partnership for cervical cancer prevention and control initiatives.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Asieris Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Junshi Biosciences: Junshi is a Chinese innovative biopharma focused on immuno-oncology and PD-1 antibodies. Comparable as a Chinese-rooted biotech with innovation pipeline and US clinical development presence.
- Photocure ASA: Photocure is the originator and licensor of both Hexvix and Cevira, operating in the same bladder cancer diagnostic and cervical HSIL therapeutic spaces. As Asieris's licensor in some markets and direct competitor in others, Photocure is the most directly comparable peer.
- BeiGene: BeiGene is a major Chinese innovative oncology biotech with global operations and Asieris's APL-1202 clinical combination partner. Comparable in oncology focus, China-US dual structure, and innovation pipeline breadth.
- Hansoh Pharmaceutical: Hansoh is a leading Chinese innovative pharmaceutical company with a strong oncology portfolio and significant commercialization scale. Comparable as a Chinese pharma with innovation focus and broad marketed product base.
- Zai Lab: Zai Lab is a Shanghai-based innovative biopharma with US operations, focused on licensing and developing oncology and specialty therapeutics. Closely comparable geography, structure, and licensing-led business model.
- Innovent Biologics: Innovent is a leading Chinese biopharma developing innovative oncology medicines with multiple approved and commercial-stage products. Comparable as a Chinese innovation-focused biotech with growing commercial portfolio.
- Hutchmed (HUTCHMED): Hutchmed is a Hong Kong/China-listed innovative oncology biopharma with US/EU operations focused on targeted therapies. Highly comparable in business model: China-rooted, US-listed, oncology-focused, multiple partnered assets.
Broad incumbents
- Merck & Co. Merck's Keytruda is approved for NMIBC, representing major competition in bladder cancer treatment. Large global pharma with extensive clinical development and commercial reach.
- Ferring Pharmaceuticals: Ferring has Adstiladrin (nadofaragene) approved for NMIBC, directly competing in bladder cancer treatment. Established specialty pharma with strong urology and women's health franchises that overlap with Asieris's focus areas.
- Bristol-Myers Squibb: BMS's Opdivo is approved for NMIBC, directly competing with Asieris's APL-1202 in bladder cancer. Large incumbent with established commercial infrastructure and substantially greater R&D resources.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Asieris Pharmaceuticals social profiles
Digital presenceAsieris Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Asieris Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles12 records
Asieris Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Asieris Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors27 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Asieris Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Asieris Pharmaceuticals
What does Asieris Pharmaceuticals do?
Asieris Pharmaceuticals is a global innovative biopharma company that develops, manufactures, and commercializes drugs for genitourinary tumors and women's health. It sells marketed pharmaceutical products including bladder cancer imaging agents, oral therapies for non-muscle invasive bladder cancer (NMIBC), renal cell carcinoma treatments, HER2+ breast cancer therapies, and the first non-surgical photodynamic therapy for cervical precancerous lesions (Cevira). It also operates proprietary drug discovery platforms (TIMN, TAIDD, DDC) supporting an in-house pipeline of small molecules, photodynamic drug-device combinations, and antibody-drug conjugates.
Is Asieris Pharmaceuticals a public or private company?
Asieris Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Asieris Pharmaceuticals founded?
Asieris Pharmaceuticals was founded in 2010. It employs 51 to 100 people.
Where is Asieris Pharmaceuticals based?
Asieris Pharmaceuticals is headquartered in Shanghai, China, in the Asia region.
How does Asieris Pharmaceuticals make money?
Three revenue lines are on record. Product Sales - Marketed Pharmaceuticals are the primary driver. The others are licensing and Milestone Payments and out-Licensing Revenue.
Who are Asieris Pharmaceuticals's main competitors?
Direct peers on record are Junshi Biosciences, Photocure ASA, BeiGene, Hansoh Pharmaceutical, Zai Lab, Innovent Biologics and Hutchmed (HUTCHMED). Broad incumbents are Merck & Co., Ferring Pharmaceuticals and Bristol-Myers Squibb.
Does Asieris Pharmaceuticals have an API?
No public API is recorded for Asieris Pharmaceuticals.
What industry is Asieris Pharmaceuticals in?
Asieris Pharmaceuticals's product category is Genitourinary Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.